CIViC Evidence Items
112 evidence items indexed
Evidence Level Distribution
CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).
AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale
Gene × Evidence Type
Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.
| Predictive | Diagnostic | Prognostic | Functional | Predispos. | Oncogenic | |
|---|---|---|---|---|---|---|
| BCR::ABL1 | 323 | 11 | ||||
| BRAF | 186 | 4 | 26 | 2 | 1 | |
| EGFR | 248 | 12 | 3 | 2 | ||
| EML4::ALK | 64 | |||||
| ERBB2 | 142 | 2 | ||||
| FLT3 | 55 | 2 | 21 | |||
| KIT | 102 | 3 | 7 | |||
| KRAS | 159 | 4 | 24 | 4 | ||
| PIK3CA | 156 | 16 | 4 | |||
| PTEN | 53 | 1 | 3 | 1 | 2 | 1 |
| TP53 | 52 | 40 | 100 | 2 | ||
| VHL | 5 | 2 | 3 | 635 | 15 |
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
| Level | Gene | Variant | Type | Direction | Significance | Disease | Drugs | Source |
|---|---|---|---|---|---|---|---|---|
| C | KIT | V560DEL | Predictive | Supports | Sensitivity/Response | Thymic Carcinoma | Imatinib | Ströbel et al., 2004 |
| D | KIT | T670I | Predictive | Supports | Resistance | Gastrointestinal Stromal Tumor | Imatinib | Garner et al., 2014 |
| D | KIT | T670I | Predictive | Does Not Support | Resistance | Gastrointestinal Stromal Tumor | Ponatinib,Sunitinib | Garner et al., 2014 |
| B | KIT | D816V | Prognostic | Supports | Poor Outcome | Acute Myeloid Leukemia | Cairoli et al., 2006 | |
| B | KIT | M541L | Diagnostic | Does Not Support | Positive | Chronic Myeloid Leukemia | Krüger et al., 2006 | |
| A | KIT | Exon 11 Mutation | Predictive | Supports | Sensitivity/Response | Gastrointestinal Stromal Tumor | Imatinib | Heinrich et al., 2003 |
| A | KIT | Exon 9 Mutation | Predictive | Supports | Sensitivity/Response | Gastrointestinal Stromal Tumor | Imatinib | Debiec-Rychter et al., 2006 |
| B | KIT | D816V | Predictive | Supports | Sensitivity/Response | Systemic Mastocytosis | Midostaurin | Gotlib et al., 2016 |
| B | KIT | D816V | Prognostic | Supports | Poor Outcome | Systemic Mastocytosis | Jawhar et al., 2016 | |
| B | KIT | Exon 11 Mutation | Predictive | Supports | Sensitivity/Response | Gastrointestinal Stromal Tumor | Imatinib | Heinrich et al., 2008 |
| D | KIT | T670I | Predictive | Supports | Resistance | Gastrointestinal Stromal Tumor | Regorafenib Anhydrous | Garner et al., 2014 |
| D | KIT | D816E | Predictive | Supports | Resistance | Gastrointestinal Stromal Tumor | Imatinib,Sunitinib | Garner et al., 2014 |
| D | KIT | V560_L576del | Predictive | Supports | Sensitivity/Response | Gastrointestinal Stromal Tumor | Imatinib,Ponatinib | Garner et al., 2014 |
| D | KIT | D816E | Predictive | Does Not Support | Resistance | Gastrointestinal Stromal Tumor | Ponatinib | Garner et al., 2014 |
| D | KIT | A829P | Predictive | Does Not Support | Resistance | Gastrointestinal Stromal Tumor | Ponatinib | Garner et al., 2014 |
| D | KIT | N822K | Predictive | Supports | Resistance | Gastrointestinal Stromal Tumor | Sunitinib,Imatinib | Garner et al., 2014 |
| D | KIT | A829P AND ( KIT W557_K558del OR KIT V560_Y578del ) | Predictive | Supports | Resistance | Gastrointestinal Stromal Tumor | Imatinib,Sunitinib | Garner et al., 2014 |
| D | KIT | L576P | Predictive | Supports | Resistance | Melanoma | Imatinib,Nilotinib,Sorafenib | Woodman et al., 2009 |
| D | KIT | L576P | Predictive | Supports | Sensitivity/Response | Melanoma | Dasatinib | Woodman et al., 2009 |
| B | KIT | Exon 11 Mutation | Prognostic | Does Not Support | Gastrointestinal Stromal Tumor | Wardelmann et al., 2006 | ||
| B | KIT | Exon 11 Mutation | Predictive | Supports | Sensitivity/Response | Melanoma | Imatinib | Hodi et al., 2013 |
| B | KIT | Exon 14 Mutation | Prognostic | Supports | Poor Outcome | Gastrointestinal Stromal Tumor | Wardelmann et al., 2006 | |
| D | KIT | V654A | Predictive | Supports | Resistance | Gastrointestinal Stromal Tumor | Imatinib | Heinrich et al., 2006 |
| C | KIT | Internal Duplication | Predictive | Supports | Sensitivity/Response | Malignant Anus Melanoma | Imatinib | Hodi et al., 2008 |
| D | KIT | L576P | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Dasatinib,Nilotinib,Imatinib | Antonescu et al., 2007 |
| B | KIT | V654A | Predictive | Supports | Sensitivity/Response | Gastrointestinal Stromal Tumor | Sunitinib | Prenen et al., 2006 |
| B | KIT | Exon 11 Mutation | Prognostic | Does Not Support | Gastrointestinal Stromal Tumor | Corless et al., 2002 | ||
| B | KIT | Exon 11 Mutation | Prognostic | Supports | Poor Outcome | Gastrointestinal Stromal Tumor | Taniguchi et al., 1999 | |
| B | KIT | rs17084733 | Diagnostic | Supports | Positive | Acral Lentiginous Melanoma | Godshalk et al., 2011 | |
| B | KIT | Mutation | Predictive | Supports | Sensitivity/Response | Melanoma | Imatinib | Guo et al., 2011 |
| B | KIT | Exon 9 Mutation | Predictive | Supports | Sensitivity/Response | Gastrointestinal Stromal Tumor | Sunitinib | Rutkowski et al., 2012 |
| C | KIT | Exon 11 Mutation | Predictive | Supports | Sensitivity/Response | Melanoma | Sunitinib | Minor et al., 2012 |
| B | KIT | Exon 9 Mutation | Predictive | Supports | Sensitivity/Response | Gastrointestinal Stromal Tumor | Sunitinib | Heinrich et al., 2008 |
| B | KIT | Amplification | Predictive | Supports | Resistance | Mucosal Melanoma | Imatinib | Hodi et al., 2013 |
| B | KIT | Exon 9 Mutation | Predictive | Supports | Sensitivity/Response | Gastrointestinal Stromal Tumor | Imatinib | Heinrich et al., 2003 |
| C | KIT | D820Y | Predictive | Supports | Resistance | Melanoma | Imatinib | Carvajal et al., 2011 |
| C | KIT | N822K | Predictive | Supports | Resistance | Gastrointestinal Stromal Tumor | Imatinib | Heinrich et al., 2006 |
| C | KIT | Y823D | Predictive | Supports | Resistance | Gastrointestinal Stromal Tumor | Imatinib | Heinrich et al., 2006 |
| C | KIT | C809G | Predictive | Supports | Resistance | Gastrointestinal Stromal Tumor | Imatinib | Heinrich et al., 2006 |
| C | KIT | D820A | Predictive | Supports | Resistance | Gastrointestinal Stromal Tumor | Imatinib | Heinrich et al., 2006 |
| C | KIT | D820G | Predictive | Supports | Resistance | Gastrointestinal Stromal Tumor | Imatinib | Heinrich et al., 2006 |
| C | KIT | D816H | Predictive | Supports | Resistance | Gastrointestinal Stromal Tumor | Imatinib | Heinrich et al., 2006 |
| C | KIT | T670I | Predictive | Supports | Resistance | Gastrointestinal Stromal Tumor | Imatinib | Heinrich et al., 2006 |
| C | KIT | V559D | Predictive | Supports | Sensitivity/Response | Gastrointestinal Stromal Tumor | Imatinib | Cameron et al., 2011 |
| B | KIT | Exon 11 Mutation | Predictive | Supports | Resistance | Gastrointestinal Stromal Tumor | Sunitinib | Heinrich et al., 2008 |
| C | KIT | W557_K558del | Predictive | Supports | Resistance | Gastrointestinal Stromal Tumor | Sunitinib | Heinrich et al., 2008 |
| D | KIT | W557_K558del | Predictive | Supports | Sensitivity/Response | Gastrointestinal Stromal Tumor | Ponatinib,Imatinib | Garner et al., 2014 |
| C | KIT | Exon 9 Mutation | Predictive | Supports | Reduced Sensitivity | Gastrointestinal Stromal Tumor | Regorafenib Anhydrous | Ben-Ami et al., 2016 |
| C | KIT | V560D | Predictive | Supports | Resistance | Gastrointestinal Stromal Tumor | Sunitinib | Heinrich et al., 2008 |
| D | KIT | V560D | Predictive | Supports | Sensitivity/Response | Gastrointestinal Stromal Tumor | Ponatinib,Regorafenib Anhydrous,Sunitinib,Imatinib | Garner et al., 2014 |
Page 1 of 3